Effect of High-intensity Low-volume Training on Insulin Sensitivity in Type 2 Diabetes (HIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02039934|
Recruitment Status : Recruiting
First Posted : January 20, 2014
Last Update Posted : September 14, 2017
High intensity interval training is applied for several diseases.
Hypothesis: High intensity interval training improves insulin sensitivity in patients with type 2 diabetes.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Other: High intensity interval training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Effect of High-intensity Low-volume Training on Insulin Sensitivity in Patients With Type 2 Diabetes and Healthy Lean Subjects|
|Study Start Date :||July 2013|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2018|
|Experimental: high intensity interval training||
Other: High intensity interval training
The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.
Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down.
- Improvement of Insulin sensitivity by high intensity interval training [ Time Frame: 2 years ]High intensity interval training leads to significant improvements in insulin action and oxidative phosphorylation in skeletal muscle.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02039934
|Contact: Julia Szendrödi, MD, PhD||0049 211 3382 email@example.com|
|Deutsches Diabetes Zentrum||Recruiting|
|Düsseldorf, Nordrhein-Westfalen, Germany, 40225|
|Contact: Julia Szendrödi, MD, PhD 0049 211 3382 203 firstname.lastname@example.org|
|Principal Investigator:||Julia Szendrödi, MD, PhD||German Diabetes Center|